Skip to content
10-K

Annual Report

Skye Bioscience, Inc. SKYE

0001516551-25-000027

← back to feed
Filed
Mar 20, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2024 · Mar 19, 2025 30.97M sh
Shares Diluted FY 2024 · Dec 31, 2023 7.01M sh
Capex FY 2024 · Dec 31, 2023 $12.55K
Operating Cash Flow FY 2024 · Dec 31, 2023 −$13.95M
Cash And Equivalents FY 2024 · Dec 31, 2023 $1.26M
Current Liabilities FY 2024 · Dec 31, 2023 $13.9M
Total Liabilities FY 2024 · Dec 31, 2023 $14.07M
Current Assets FY 2024 · Dec 31, 2023 $11.65M
Total Assets FY 2024 · Dec 31, 2023 $11.94M
Eps Diluted FY 2024 · Dec 31, 2023 −$5.37
Eps Basic FY 2024 · Dec 31, 2023 −$5.37
Sga Expense FY 2024 · Dec 31, 2023 $7.85M
Net Income FY 2024 · Dec 31, 2023 −$37.64M
Operating Income FY 2024 · Dec 31, 2023 −$34.74M
Stockholders Equity FY 2024 · Dec 31, 2022 −$3.01M